Question explored with the scientific record
Conversation so far
- 1 CCSVI success of angioplasty
- 2 CCSVI success of angioplasty
Answered on this page ↓
CCSVI success of angioplasty
The short version: the vein often closes again, and when it stays open the MS still does not reliably improve.
Patency is the weak link. In one series, 18-month patency was 53% in the jugular veins versus 96% in the azygos vein [2]. A retrospective series of 150 patients found high-pressure balloons were needed to fully open these lesions, and sizing the balloon by intravascular ultrasound cut the complication rate from 16% to 1.3% [4]. That is a real technical finding, but it is about avoiding injury, not about MS.
The clinical numbers split by design, and the split is the story.
| Design | Patients | Result |
|---|---|---|
| Sham-controlled trial | 9 treated, 10 sham | No clinical benefit; more MRI activity in treated [5] |
| Review of 4 RCTs | Pooled randomized | No consistent clinical efficacy [1] |
| 4-year follow-up, no control | 366 | 98.5% fatigue "improvement" in relapsing-remitting [6] |
| Same cohort, progressive MS | 62 and 40 | 6.5% and 5.0% still improved at 36-48 months [6] |
| YouTube self-report | 224 | 86% any improvement, 18% mobility [3] |
| Retrospective series | 89 | 54% symptomatic improvement, no control [4] |
The four-year follow-up is the most instructive. Even in an uncontrolled, self-selected cohort, the progressive patients lost their benefit almost entirely [6]. Seven progressive patients developed jugular thrombosis after a second procedure, all in veins that were already underdeveloped [6]. The Brave Dreams expanded analysis did report fewer new MRI lesions in the treated arm at 12 months [1], but that is a subgroup re-analysis, not the primary result.
My call: angioplasty for CCSVI is not a reliable treatment for MS. Patency is mediocre, the controlled trials are negative, and the benefit that does appear is subjective and fades in progressive disease. Confidence: moderate.
Sources used 6
-
An overview of randomized controlled trials on endovascular treatment for chronic cerebrospinal venous insufficiency in multiple sclerosis patients
A narrative overview of four RCTs found no consistent clinical efficacy of venous angioplasty for CCSVI in multiple sclerosis, though selected MRI/subgroup benefits and rare serious adverse events warrant targeted trials.
DOI: 10.1055/a-1061-3205 -
The chronic cerebrospinal venous insufficiency syndrome
This narrative review argues that CCSVI, marked by extracranial venous stenoses, is associated with MS and may be treated by balloon angioplasty, though controlled evidence remains limited.
DOI: 10.1258/phleb.2010.009083 -
Social Media Representation of Chronic Cerebrospinal Venous Insufficiency Intervention for Multiple Sclerosis
YouTube content about CCSVI angioplasty for multiple sclerosis was predominantly favorable: 86% of 224 people with MS reported symptom improvement, and most health-care professional videos were positive, though mobility improvement was limited and scientific evidence was lacking.
DOI: 10.7224/1537-2073.2014-073 -
Abstract No. 47: High pressure balloon angioplasty to treat internal jugular vein stenoses in patients with CCSVI
Conference abstracts report that intravascular ultrasound (IVUS) improves detection and treatment of venous lesions in CCSVI, with high-pressure angioplasty showing short-term quality-of-life benefits and a 54% symptomatic improvement rate.
DOI: 10.1016/j.jvir.2011.12.083 -
Venous angioplasty for “CCSVI” in multiple sclerosis
An editorial assessing the randomized, double-blind, sham-controlled trial of venous angioplasty for CCSVI in multiple sclerosis, concluding no clinical benefit and possible increased disease activity on MRI, and arguing against further trials or use of the procedure.
DOI: 10.1212/WNL.0000000000000651 -
May symptoms of chronic cerebrospinal venous insufficiency be improved by venous angioplasty? An independent 4-year follow up on 366 cases
In an uncontrolled four-year follow-up of 366 multiple sclerosis patients with CCSVI, venous angioplasty was followed by sustained symptom improvement mainly in relapsing-remitting disease, while progressive patients often improved briefly and then relapsed.
DOI: 10.4081/vl.2015.5400